Summary:
In patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin,
empagliflozin as an add-on therapy significantly improved glycemic indices and cardiometabolic parameters compared to sitagliptin added to metformin, though it was associated with higher rates of genital infections.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes mellitus (T2DM), inadequately controlled on metformin treatment. |
| Intervention | Empagliflozin (10 mg daily) as an add-on therapy to metformin. |
| Comparison | Sitagliptin (100 mg daily) as an add-on therapy to metformin. |
| Outcome | Empagliflozin significantly improved HbA1c levels and weight reduction compared to sitagliptin, while also improving cardiometabolic parameters. However, empagliflozin was associated with an increased risk of genital infections. |
Source: Naimeh Mesri Alamdari, et al. “Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial.” Read article here.
